Skip to main content

Table 1 Age, disease status, stage, response to last therapy and clinical outcome for subjects receiving a complete set of three injections

From: First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

Subject ID Age (years) Treatment history Stage Response to Prior Treatment Dose (mL) Immune Response Time to Progression* (months)
Breast Cancer
01-13 44 cytotoxic therapy, hormonal therapy, immunotherapy (Avastin), radiation IV SD 0.25 Yes 2 a
04-06 61 concurrent hormonal therapy IV SD 0.25 Yes > 8
04-19 46 cytotoxic therapy, concurrent hormonal therapy, radiation IV SD 1.0 Yes 2.5 a
Ovarian Cancer
05-14 50 platinin-based cytotoxic therapy III CR 0.25 Yes 4 a
05-15 48 platinin-based cytotoxic therapy III CR 0.25 Yes 5 a
02-01 49 platinin-based cytotoxic therapy III CR 0.25 No > 9
05-07 54 platinin-based cytotoxic therapy III CR 1.0 Yes > 8
02-09 67 platinin-based cytotoxic therapy, immunotherapy (Avastin) IV CR 1.0 Yes > 8.5
01-22 49 platinin-based cytotoxic therapy III CR 1.0 Yes > 8
Prostate Cancer
03-17 60 hormonal therapy, anti-androgen therapy Unknown PD 0.25 Yes 2 a
01-04 67 hormonal therapy, cytotoxic therapy, anti-androgen therapy, immunotherapy (Provenge), radiation IV PD 0.25 No 2 a
02-05 63 ongoing hormonal therapy, cytotoxic therapy, concurrent anti-androgen therapy IV PD 0.25 Unknown UE b
03-16 65 hormonal therapy, cytotoxic therapy, anti-androgen therapy, radiation IV PD 0.25 No 2.3 a
02-02 66 hormonal therapy, cytotoxic therapy, anti-androgen therapy, radiation IV PD 0.25 Unknown 5.7 a
01-03 76 hormonal therapy, anti-androgen therapy, radiation IV SD 0.25 No UE b
02-12 54 hormonal therapy, concurrent anti-androgen therapy, radiation IV SD 1.0 Unknown 2.3 a
01-18 68 hormonal therapy, anti-androgen therapy, radiation IV PD 1.0 Yes 2.3 a
02-20 64 hormonal therapy, anti-androgen therapy, radiation IV Unknown 1.0 Unknown 2.3 a
03-21 74 hormonal therapy, anti-androgen therapy, radiation IV PD 1.0 No 2.3 a
04-10 63 hormonal therapy, concurrent anti-androgen therapy, radiation IV PD 1.0 Yes 3.5 c
03-08 60 hormonal therapy, anti-androgen therapy, radiation IV PD 1.0 No 6.5 a
02-11 68 hormonal therapy, anti-androgen therapy, radiation IV PD 1.0 No 7.3 a
  1. CR complete response, SD stable disease, PD progressive disease, UE unevaluable.
  2. *since study day 0.
  3. aDisease progression necessitating some other type of treatment.
  4. bWithdrawal of consent.
  5. cDeath due to disease progression.